CXCR3-Mediated Cell-Cell Communication in Glaucoma
CXCR3 介导的青光眼细胞间通讯
基本信息
- 批准号:10684834
- 负责人:
- 金额:$ 45.97万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-01 至 2027-07-31
- 项目状态:未结题
- 来源:
- 关键词:AstrocytesAttenuatedAutoimmuneAxonBindingBlindnessBone MarrowC3AR1 geneCXC chemokine receptor 3CXCL10 geneCXCR3 geneCardiovascular DiseasesCell CommunicationCell DeathCellsChronicClinicClinical TrialsCommunicationComplement 3DataDegenerative DisorderDiseaseDisease ProgressionDominant-Negative MutationFamilyFunctional disorderGene DeliveryGlaucomaHistologyImageImmuneImmunologic FactorsImmunotherapeutic agentIn VitroInfiltrationInflammationInflammatoryKnockout MiceKnowledgeLeukocyte TraffickingLeukocytesMacrophageMediatingMembraneMethodologyMicrogliaMicrospheresModelingMusNerve DegenerationNeurobiologyNeurodegenerative DisordersNeurogliaNeuronal InjuryNon-Steroidal Anti-Inflammatory AgentsOptic NerveOptic Nerve InjuriesOpticsOrganismPathogenesisPathologicPathway interactionsPeptidesPhase I Clinical TrialsPhysiologic Intraocular PressurePlayReperfusion TherapyResearchRetinaRetinal Ganglion CellsRisk FactorsRoleSafetySeriesSignal InductionSignal TransductionStrategic PlanningSystemT-LymphocyteTestingTherapeutic InterventionTimeTissuesUp-RegulationVisionantagonistaxonal degenerationcell injurycell typechemokinechemokine receptorconditional knockoutgene therapyinjuredloss of functionmonocytemouse modelneuroprotectionnon-invasive imagingnovelnovel therapeutic interventionoptic nerve disorderpreventreal-time imagesreceptorrecruitretinal ganglion cell degenerationretinal ischemiaretinal neurontargeted treatmenttranslational potential
项目摘要
CXCR3-mediated Cell-Cell Communication in Glaucoma
SUMMARY
Glaucoma, which is characterized as progressive retinal ganglion cell (RGC) death and optic nerve
degeneration, is the second leading cause of irreversible blindness worldwide. Increased intraocular pressure
(IOP) is a main risk factor for glaucoma and is the only target for therapeutic intervention. However, lowering
IOP does not always stop the disease progression. There is an unmet need to understand the mechanisms of
neurodegeneration in glaucoma and identify novel targets for glaucoma therapy. Cell-cell communication plays
a key role in pathophysiological changes in multicellular organisms. Chemokines are a family of structurally
related pro-inflammatory peptides that plays a central role in the communication between injured/infected cells
and other cell types via binding to specific chemokine receptors on the membrane of their respective target
cells. While it has been well appreciated that chemokines are critically involved in the pathogenesis of
inflammatory, autoimmune, infectious, oncologic, cardiovascular and neurodegenerative diseases, the role of
retina-derived chemokines in glaucomatous optic neuropathy is largely unknown. CXCL10 is a chemokine and
its receptor is CXCR3. This pathway has a key role in inflammation by recruiting and activating several types of
leukocytes including macrophage/microglia and T cells. In this project, we hypothesize that the
CXCL10/CXCR3 pathway has an essential role in the communication between RGCs and other cell types
(immune cells and astrocytes) during glaucoma and blocking this pathway alleviates dysfunction/degeneration
of RGCs and their axons. We propose the following three aims: (Aim1) Test the hypothesis that CXCR3
signaling plays a key role in the communication between RGCs and immune cells, which contributes to
glaucomatous optic neuropathy; (Aim2) Test the hypothesis that CXCR3 induces toxic RGC-astrocyte
crosstalk via CXCR3-mediated C3/C3aR signaling; (Aim3) Test the hypothesis that blocking CXCR3 is an
effective approach to treat glaucoma. We will integrate a series of novel methodologies in the studies, such as
bone marrow chimeric mice, CXCR3 conditional knockout mice, AAV2-mediated gene therapy, real-time
imaging of leukocyte trafficking, tissue optical clearing, and clinic-relevant non-invasive imaging and functional
tests. Taken together, our proposed study will provide important new knowledge on CXCL10/CXCR3-mediated
cell-cell communication in neurodegeneration and may identify the novel therapeutic approaches to manage
glaucomatous optic neuropathy. This proposal is in line with “Research Needs, Gaps, and Opportunities”
identified in the NEI Strategic Plan: 1) The role of non-neuronal cells such as glia is critical for understanding
degenerative diseases; 2) Investigate neurobiology roles for immune factors that challenge orthodoxy and
examine whether these “immune” factors are playing nontraditional roles for vision function; 3) Identify targeted
therapeutics or non-steroidal anti-inflammatory drugs for immune-related diseases.
青光眼中cxcr3介导的细胞间通讯
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Gracie Vargas其他文献
Gracie Vargas的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Gracie Vargas', 18)}}的其他基金
CXCR3-Mediated Cell-Cell Communication in Glaucoma
CXCR3 介导的青光眼细胞间通讯
- 批准号:
10539828 - 财政年份:2022
- 资助金额:
$ 45.97万 - 项目类别:
Nonlinear Optical Staging of Epithelial Neoplasms
上皮肿瘤的非线性光学分期
- 批准号:
8018495 - 财政年份:2008
- 资助金额:
$ 45.97万 - 项目类别:
Nonlinear Optical Staging of Epithelial Neoplasms
上皮肿瘤的非线性光学分期
- 批准号:
7759562 - 财政年份:2008
- 资助金额:
$ 45.97万 - 项目类别:
Nonlinear Optical Staging of Epithelial Neoplasms
上皮肿瘤的非线性光学分期
- 批准号:
8410630 - 财政年份:2008
- 资助金额:
$ 45.97万 - 项目类别:
Nonlinear Optical Staging of Epithelial Neoplasms
上皮肿瘤的非线性光学分期
- 批准号:
7571583 - 财政年份:2008
- 资助金额:
$ 45.97万 - 项目类别:
Nonlinear Optical Staging of Epithelial Neoplasms
上皮肿瘤的非线性光学分期
- 批准号:
7476223 - 财政年份:2008
- 资助金额:
$ 45.97万 - 项目类别:
相似海外基金
A platform for rapidly generating live attenuated enterovirus vaccines
快速生成减毒肠道病毒活疫苗的平台
- 批准号:
24K02286 - 财政年份:2024
- 资助金额:
$ 45.97万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
I-Corps: Translation potential of an efficient method to generate live-attenuated and replication-defective DNA viruses for vaccine development
I-Corps:一种有效方法的转化潜力,可生成用于疫苗开发的减毒活病毒和复制缺陷型 DNA 病毒
- 批准号:
2420924 - 财政年份:2024
- 资助金额:
$ 45.97万 - 项目类别:
Standard Grant
Developing a robust native extracellular matrix to improve islet function with attenuated immunogenicity for transplantation
开发强大的天然细胞外基质,以改善胰岛功能,并减弱移植的免疫原性
- 批准号:
10596047 - 财政年份:2023
- 资助金额:
$ 45.97万 - 项目类别:
Live attenuated non-transmissible (LANT) Klebsiella pneumoniae vaccines
肺炎克雷伯氏菌减毒非传染性 (LANT) 活疫苗
- 批准号:
10742028 - 财政年份:2023
- 资助金额:
$ 45.97万 - 项目类别:
Protecting Pigs From Enzootic Pneumonia: Rational Design Of Safe Attenuated Vaccines.
保护猪免受地方性肺炎:安全减毒疫苗的合理设计。
- 批准号:
BB/X017540/1 - 财政年份:2023
- 资助金额:
$ 45.97万 - 项目类别:
Research Grant
A “Goldilocks” live attenuated poultry vaccine for Infectious Coryza
用于传染性鼻炎的“Goldilocks”家禽减毒活疫苗
- 批准号:
LP210301365 - 财政年份:2023
- 资助金额:
$ 45.97万 - 项目类别:
Linkage Projects
A novel live-attenuated Zika vaccine with a modified 5'UTR
一种带有改良 5UTR 的新型寨卡减毒活疫苗
- 批准号:
10730832 - 财政年份:2023
- 资助金额:
$ 45.97万 - 项目类别:
Combating melanoma with an attenuated bacterial therapeutic
用减毒细菌疗法对抗黑色素瘤
- 批准号:
10659841 - 财政年份:2023
- 资助金额:
$ 45.97万 - 项目类别:
Investigating Host and Viral Factors for Improved Design of Future Live Attenuated Vaccines for IBV
研究宿主和病毒因素以改进未来 IBV 减毒活疫苗的设计
- 批准号:
BB/V016067/1 - 财政年份:2022
- 资助金额:
$ 45.97万 - 项目类别:
Research Grant
L2M NSERC-Bioengineering attenuated Sclerotinia sclerotiorum strains as bioherbicide for cereal production and lawn management
L2M NSERC-生物工程减毒核盘菌菌株作为谷物生产和草坪管理的生物除草剂
- 批准号:
576545-2022 - 财政年份:2022
- 资助金额:
$ 45.97万 - 项目类别:
Idea to Innovation